Press Release

Celltrion USA Announces U.S. FDA Approval of Yuflyma® (adalimumab-aaty), a High-Concentration and Citrate-Free Formulation of Humira® (adalimumab) Biosimilar 2023-05-24

Celltrion USA Announces U.S. FDA Approval of Yuflyma® (adalimumab-aaty), a High-Concentration and Citrate-Free Formulation of Humira® (adalimumab) Biosimilar Yuflyma is FDA approved to treat eight conditions including Crohn’s disease and ulcerative colitis...

Celltrion Healthcare Launches IBD Awareness Campaign in Collaboration With Leading Patient Organisation, EFCCA, for World IBD Day 2023 2023-05-19

Celltrion Healthcare Launches IBD Awareness Campaign in Collaboration With Leading Patient Organisation, EFCCA, for World IBD Day 2023 • Celltrion Healthcare and EFCCA have partnered to launch the Where’s CC? (Crohn’s & Colitis) campaign for Wo...

게시물 검색

98

Celltrion Healthcare Presents Efficacy and Safety ..

Celltrion Healthcare Presents Efficacy and Safety Data From Global Phase III LIBERTY Trial, at the 18thECCO Congress • Latest data from the global Phase III pivotal data for LIBERTY studies show maintenance therapy with subcutaneou…

2023-03-03
97

Celltrion USA Appoints Thomas Nusbickel as Chief C..

Celltrion USA Appoints Thomas Nusbickel as Chief Commercial Officer Seasoned commercial operations executive brings three decades of global biopharmaceutical industry experience to Celltrion USA’s leadership team February 06, 2023,…

2023-02-06
96

Celltrion USA announces submission of the Biologic..

Celltrion USA announces submission of the Biologics License Application (BLA) of novel subcutaneous formulation of CT-P13 to U.S. Food and Drug Administration CT-P13 SC is a novel subcutaneous formulation of infliximab The Biologics Lic…

2022-12-22
95

Celltrion USA receives U.S. FDA approval for its o..

Celltrion USAreceives U.S. FDA approval for its oncology biosimilar Vegzelma® (bevacizumab-adcd) for the treatment of six types of cancer · Vegzelma® is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA · Vegzelma…

2022-09-28
94

European Commission approves Celltrion Healthcare’..

European Commission approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the treatment of multiple types of cancer · Vegzelma™ offers European patients living with certain types of breast, lung, renal, colon, rectum…

2022-08-19
93

Celltrion Healthcare receives CHMP positive opinio..

Celltrion Healthcare receives CHMP positive opinion for biosimilar bevacizumab, Vegzelma™ (CT-P16) • Vegzelma™ (CT-P16), a biosimilar candidate referencing Avastin®(bevacizumab)1, is Celltrion’s third oncology biosimilar…

2022-06-27
92

New data show statistically greater improvements i..

New data show statistically greater improvements in clinical outcomes with subcutaneous infliximab, compared to intravenous infliximab, in patients with rheumatoid arthritis - Presented today at EULAR 2022, data from a new post-hoc analysis s…

2022-06-02
91

Celltrion Healthcare wins tender to supply Remsima..

Celltrion Healthcare wins tender to supply Remsima® to the Brazilian Federal Government • Remsima® is the third biosimilar product for Celltrion Healthcare to win tender in Brazil following Truxima® and Herzuma® • The company will be supplying R…

2022-03-24
90

Switching to subcutaneous infliximab leads to high..

Switching to Subcutaneous Infliximab Leads to Higher Trough Level and Low Risk of Relapse in Patients with Inflammatory Bowel Disease - New data from the REMSWITCH study shows switching from intravenous (IV) to subcutaneous (SC) infliximab leads t…

2022-03-02
89

Celltrion Submits IND Application to Initiate a Gl..

Celltrion Submits Investigational New Drug (IND) Application to Initiate a Global Phase III Clinical Trial Evaluating an Inhaled COVID-19 Antibody Cocktail Therapy Celltrion submitted an IND application for a global Phase III clinical trial of …

2022-02-07

CelltrionHealthcare